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Abstract
IMPORTANCE Apathy is a frequent neuropsychiatric symptom in dementia of Alzheimer type and
negatively affects the disease course and patients’ and caregivers’ quality of life. Effective treatment
options are needed.
OBJECTIVE To examine the efficacy and safety of the dopamine and noradrenaline reuptake
inhibitor bupropion in the treatment of apathy in patients with dementia of Alzheimer type.
DESIGN, SETTING, AND PARTICIPANTS This 12-week, multicenter, double-blind, placebo-
controlled, randomized clinical trial was conducted in a psychiatric and neurological outpatient
setting between July 2010 and July 2014 in Germany. Patients with mild-to-moderate dementia of
Alzheimer type and clinically relevant apathy were included. Patients with additional clinically
relevant depressed mood were excluded. Data analyses were performed between August 2018 and
August 2019.
INTERVENTIONS Patients received either bupropion or placebo (150 mg for 4 weeks plus 300 mg
for 8 weeks). In case of intolerability of 300 mg, patients continued to receive 150 mg throughout
the study.
MAIN OUTCOMES AND MEASURES Change on the Apathy Evaluation Scale–Clinician Version
(AES-C) (score range, 18-72 points) between baseline and week 12 was the primary outcome
parameter. Secondary outcome parameters included measures of neuropsychiatric symptoms,
cognition, activities of daily living, and quality of life. Outcome measures were assessed at baseline
and at 4, 8, and 12 weeks.
RESULTS A total of 108 patients (mean [SD] age, 74.8 [5.9] years; 67 men [62%]) were included in
the intention-to-treat analysis, with 54 randomized to receive bupropion and 54 randomized to
receive placebo. The baseline AES-C score was comparable between the bupropion group and the
placebo group (mean [SD], 52.2 [8.7] vs 50.4 [8.2]). After controlling for the baseline AES-C score,
site, and comedication with donepezil or galantamine, the mean change in the AES-C score between
the bupropion and placebo groups was not statistically significant (mean change, 2.22; 95% CI, –0.47
to 4.91; P = .11). Results on secondary outcomes showed statistically significant differences between
bupropion and placebo in terms of total neuropsychiatric symptoms (mean change, 5.52; 95% CI,
2.00 to 9.04; P = .003) and health-related quality of life (uncorrected for multiple comparisons;
mean change, –1.66; 95% CI, –3.01 to –0.31; P = .02) with greater improvement in the placebo group.
No statistically significant changes between groups were found for activities of daily living (mean
change, –2.92; 95% CI, –5.89 to 0.06; P = .05) and cognition (mean change, –0.27; 95% CI, –3.26 to
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Abstract (continued)
2.73; P = .86). The numbers of adverse events (bupropion group, 39 patients [72.2%]; placebo
group, 33 patients [61.1%]) and serious adverse events (bupropion group, 5 patients [9.3%]; placebo
group, 2 patients [3.7%]) were comparable between groups.
CONCLUSIONS AND RELEVANCE Although it is safe, bupropion was not superior to placebo for the
treatment of apathy in patients with dementia of Alzheimer type in the absence of clinically relevant
depressed mood.
TRIAL REGISTRATION EU Clinical Trials Register Identifier: 2007-005352-17
JAMA Network Open. 2020;3(5):e206027. doi:10.1001/jamanetworkopen.2020.6027
Introduction
As the most frequent neuropsychiatric symptom in patients with dementia of Alzheimer type (DAT),
apathy greatly affects the disease course, patients’ activities of daily living, and quality of life.1-3
Apathy increases caregiver burden4 and is associated with increased mortality.5 Apathy can occur
during all stages of DAT and may even appear in the preclinical phase of Alzheimer disease (AD).6
Antidementia drugs, such as acetylcholinesterase inhibitors, are only of very limited efficacy in the
treatment of apathy.7 A recent Cochrane review8 found only 4 randomized clinical trials with the
primary goal of improving apathy. Thus, there is a need to improve treatment options.
The concept of apathy in DAT has been substantially developed over the last years.9 Apathy is
defined as a lack of motivation for goal-directed behavior or thought10 without sadness or
hopelessness. Although apathy was long considered to be linked with depression, it is now
conceptualized as an independent neuropsychiatric symptom.10,11 In a study12 of 2354 patients with
DAT, apathy was identified as an independent symptom cluster in addition to hyperactivity,
psychosis, and affective symptoms (including depression). Recently, apathy has been classified as a
multidimensional deficit with emotional, behavioral, and cognitive domains.10 Although loss of
interest might be partly associated with depression, emotional apathy with symptoms of emotional
neutrality seems not to be associated with depression.13,14
The neural basis of apathy in DAT has been examined in several neuroimaging studies.15 Among
other regions, the dopamine-related frontostriatal circuitry including the anterior cingulate cortex
and the prefrontal cortex seem to be involved.16,17 From a neurotransmitter perspective, low levels of
dopamine are associated with reduced motivational and reward-driven behavior and have been
linked to apathy.18 Similarly, an inverse association has been reported between dopamine and
noradrenaline transporter binding in the ventral striatum with higher apathy scores in patients with
Parkinson disease.19
On the basis of these findings, effective treatment of apathy may be achieved with a
pharmacological compound that increases dopaminergic and noradrenergic neurotransmission.
Support for this approach comes from a recent randomized clinical trial20 of 60 male veterans with
DAT that showed a beneficial effect of the dopamine and noradrenaline reuptake inhibitor
methylphenidate on apathy. In that study, patients with DAT with and without co-occurring
symptoms of depression were included. Methylphenidate has a short half-life and can only be
prescribed according to controlled substances laws in some countries. Therefore, other drugs might
even be more suited for the treatment of apathy in DAT. Bupropion is a dopamine and noradrenaline
reuptake inhibitor licensed for use as an antidepressant. Bupropion has been shown to increase
psychomotor activity in a mouse model of DAT.21 Case reports in frontotemporal dementia22 and
poststroke apathy23 supported bupropion as a potentially effective drug for the treatment of apathy.
Here, we report a 12-week, multicenter, double-blind, placebo-controlled, randomized clinical
trial that tested the effect of bupropion on apathy in patients with DAT. Patients with concomitant
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depressed mood were excluded to avoid potential effects on apathy by improvement of
depressed mood.
Methods
Study Design
This study was designed as a 12-week, multicenter, double-blind, placebo-controlled, randomized
clinical trial in patients with mild-to-moderate DAT with clinically relevant apathy and without
clinically relevant symptoms of depressed mood. The trial was conducted in a psychiatric and
neurological outpatient setting between July 2010 and July 2014 in Germany. The study was
conducted according to the Declaration of Helsinki and was approved by the institutional review
board of each participating center. The study was monitored by an independent Data and Safety
Monitoring Board. This study follows the Consolidated Standards of Reporting Trials (CONSORT)
reporting guideline. The complete study protocol can be found in Supplement 1.
Before screening, all patients and their caregivers gave written informed consent to the full
study protocol. In case a patient was incapable of providing informed consent because of progressed
cognitive impairment, a legal guardian substituted. After an initial screening period of 4 weeks and
the baseline assessment, visits were scheduled at 4, 8, and 12 weeks after baseline. In addition, 2
safety visits were conducted at 2 and 6 weeks after baseline.
Inclusion and Exclusion Criteria
Patients were recruited only in outpatient settings. The diagnosis of DAT was established according
to criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association (probable AD).24 Patients were eligible for
the study if they were aged 55 to 90 years, had a Mini-Mental State Examination (MMSE) score
between 10 and 25, and had a caregiver who was willing to participate as a study partner.
The presence of clinically relevant apathy was operationalized by applying the revised Marin
and Starkstein apathy in AD criteria.25 In addition, all patients had to score at least 4 points on the
apathy item of the Neuropsychiatric Inventory (NPI).26 A score of 4 points or higher was considered
to indicate a clinically meaningful neuropsychiatric symptom on each domain of the NPI. To
investigate the effect of bupropion specifically on apathy and to prevent contamination by effects on
depressed mood, patients who either fulfilled the major depressive episode Diagnostic and Statistical
Manual of Mental Disorders (Fourth Edition) criterion of depressed mood or scored 4 points or higher
on the dysphoria and depression item of the NPI were excluded.
Patients who either were not receiving antidementia drug treatment or who had been receiving
stable treatment with acetylcholinesterase inhibitors and/or memantine for at least 3 months before
baseline were included. Patients with dementia other than DAT were excluded. Patients with severe
somatic or psychiatric conditions that had led to inpatient hospital treatment during the last 6
months before study participation were not considered. Because of the particular potential adverse
effects and contraindications of bupropion, patients with a history of seizures, cerebral tumors,
severe traumatic brain injury, or clinically relevant kidney or liver dysfunction were excluded. Patients
with unstable diabetes were also excluded. Concomitant treatment with drugs that potentially lower
the seizure threshold or that are metabolized by cytochrome P450 isoenzyme 2D6 or that may
interfere with bupropion metabolism was prohibited. Also, continuous treatments with antipsychotic
or antidepressant medication, benzodiazepines, dopaminergic medication, monoamine oxidase
inhibitors, or amantadine within the last 4 weeks before study participation were exclusion criteria.
Study Treatment Groups
After baseline, patients were randomized to receive either bupropion or placebo. The initial dose of
bupropion was 150 mg once daily or 1 identical placebo dose, respectively. If the tolerability was
sufficient, the dose was increased to 150 mg twice daily or placebo twice daily after 4 weeks. In case
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of intolerable adverse effects, the dose could be decreased again to 150 mg once daily or 1 placebo
dose and continued at that dose until the end of the study. Study adherence was measured by
medication count and caregiver feedback at each follow-up visit. Randomization was conducted at
baseline by the Center for Clinical Studies, University of Cologne, and included a random block design
with blocks of variable length providing a balanced increase of participating patients in both
treatment groups (bupropion:placebo = 1:1). Randomization was stratified for comedication with
donepezil or galantamine because both are metabolized by cytochrome P450 isoenzyme 2D6, which
is mildly inhibited by bupropion.
Efficacy Measures
The primary outcome measure was the mean change in the Apathy Evaluation Scale–Clinician Version
(AES-C) score.27,28 This scale consists of 18 questions that are answered on a Likert scale from 1 to 4,
resulting in a range of 18 to 72 points. Higher scores indicate greater apathy. The German version of
the scale has been shown to be reliable and valid.28 In addition, the AES-C can be divided into an
emotional subfactor (range, 2-8), a behavioral subfactor (range, 5-20), a cognitive subfactor (range,
8-32), and a subfactor that includes other items (range, 3-12). The subfactors of the AES-C were
analyzed as secondary outcome measures. Additional secondary outcome measures were the NPI
total score (range, 0-144),26 the Caregiver Distress Scale of the NPI (range, 0-60),26 the Alzheimer
Disease Cooperative Study–Activities of Daily Living Scale (range, 0-78),29 self and proxy ratings of
the Quality of Life-AD Scale (QoL-AD) (range, 13-53),30 the cognitive subscale of the Alzheimer
Disease Assessment Scale (ADAS-Cog) (range, 0-80),31 the MMSE (range, 0-30),32 and the
Montgomery-Asberg Depression Rating Scale (MADRS) (range, 0-60).33 Higher values on the NPI,
the NPI Caregiver Distress Scale, the MADRS, and the cognitive subscale of the Alzheimer Disease
Assessment Scale reflect worse outcomes. Higher values on the Alzheimer Disease Cooperative
Study–Activities of Daily Living Scale, MMSE, and the QoL-AD reflect better outcomes.
The NPI and the NPI Caregiver Distress Scale were assessed at the screening visit, at baseline,
and at 4, 8, and 12 weeks of follow-up. The MMSE was administered at the screening visit and at 4, 8,
and 12 weeks of follow-up. All other scales including the AES-C were assessed at baseline at the
4-week, 8-week, and 12-week visits.
Safety
Safety was examined by assessing vital signs, electrocardiogram, change in comedication, physical
examination, and assessment of suicidality by clinical examination at each visit. Adverse events (AEs)
were monitored throughout the study.
Statistical Analysis
All statistical analyses were performed at the Institute of Medical Statistics and Bioinformatics at the
University of Cologne, Germany. Initial power calculation suggested a sample size of 216 patients
(108 bupropion and 108 placebo) to be enrolled to test for a 5-point difference on the primary
outcome (AES-C) of which an SD of 11.5 points has been reported in a comparable patient sample.28
This would equal an effect size of Cohen d = 0.43. The target number included an estimated dropout
rate of 20%. Because of the low recruitment rate, the study sponsor, the funding agency, the
responsible biometrician, the ethics committee, and the Data and Safety Monitoring Board agreed to
insert an interim analysis based on 50% of the planned subjects (ie, based on 108 participants plus
2 exclusions at baseline). For the same reason and also because of the missing trend-level effect in
favor of bupropion, the parties later agreed to prematurely terminate the study (ie, declaring the
interim analysis as the final one). A trend effect was considered a greater but nonsignificant effect of
bupropion on apathy compared with placebo. The clinical study protocol was amended accordingly.
On the basis of the reduced sample size of 108 participants (ie, 54 per group), an effect size of 0.54
(ie, 6.3 points between-group difference divided by 11.5 points within-group SD) could still be
detected with 80% power at 2-sided type I error of 5% (by the 2-sample t test).
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The 2 treatment groups were compared with χ2 tests for categorical variables and with indepen-
dent t tests for continuous variables on demographic characteristics and baseline clinical characteris-
tics, including primary and secondary outcome parameters. The intention-to-treat (ITT) population was
used to perform primary and secondary efficacy analyses. The ITT population consisted of all patients
who received at least 1 dose of the study medication (bupropion or placebo) and who took part in at
least 1 follow-up visit with completion of the AES-C score. The missing completely at random analysis
for missing values was applied.34 The primary efficacy analysis (mixed-effect model repeated mea-
sures) tested the difference of the individual change of the AES-C total scores between baseline and the
12-week visit between the 2 treatment groups. The mixed-effect model repeated-measures model was
corrected for the baseline AES-C score, site, and comedication with donepezil or galantamine. Both
donepezil and galantamine are partly metabolized by cytochrome P450 isoenzyme 2D6, which is inhib-
ited by bupropion. Thus, bupropion may affect the plasma concentration of donepezil and galantamine,
which may, in turn, change the mild effect of these compounds on apathy. Rivastigmine and memantine
are not metabolized by cytochrome P450 isoenzyme 2D6. The secondary efficacy analyses were con-
ducted in the same manner and stratified for the baseline score, site, and comedication with donepezil
or galantamine. The safety analysis compared the number of AEs and serious AEs between the treat-
ment groups applying the χ2 test. The same procedure was conducted with the per-protocol popula-
tion, which included all patients who completed all study visits and who adhered to study medication.
Statistical significance was set at 2-sided P < .05. The statistical analysis (comparison of mean values) of
secondary outcomes essentially is descriptive (ie, without controlling the familywise error). All statisti-
cal analyses were performed using SPSS statistical software version 22 (IBM Corp). Data analyses were
performed between August 2018 and August 2019.
Results
Of 140 screened patients, 108 were included in the ITT analysis (mean [SD] age, 74.8 [5.9] years; 67
men [62%]). The study flow is depicted in Figure 1. Of the 140 screened patients, 110 were
Figure 1. Flow Diagram of Patient Progress Through the Trial of Bupropion vs Placebo for the Treatment
of Apathy in Alzheimer Disease
140 Screened for eligibility
110 Randomized
30 Excluded
15 Screening failed
4 Declined participation
11 Other reasons
55 Randomized to placebo
54 Received allocated intervention
1 Withdrawal of informed consent
Analysis sets
54 Intention to treat
44 Per protocol
Analysis sets
54 Intention to treat
37 Per protocol
55 Randomized to bupropion
54 Received allocated intervention
1 Withdrawal of informed consent
10 Lost to follow-up
2 Protocol violation
1 Withdrawal of informed consent
1 Withdrawal by physician
3 Nonadherence
3 Other reasons
17 Lost to follow-up
2 Protocol violation
3 Withdrawal of informed consent
2 Withdrawal by physician
5 Adverse events
3 Nonadherence
2 Other reasons
JAMA Network Open | Psychiatry Bupropion for the Treatment of Apathy in Alzheimer Disease
JAMA Network Open. 2020;3(5):e206027. doi:10.1001/jamanetworkopen.2020.6027 (Reprinted) May 28, 2020 5/14
Downloaded From: https://jamanetwork.com/ by a Universitatsbibliothek Bern User  on 07/27/2020
randomized. Before the first application of the study medication, 1 patient withdrew in each
treatment group. Of the 108 patients who participated, 10 in the placebo group and 17 in the
bupropion group dropped out of the study. Thus, the ITT population consisted of 54 patients in each
treatment group, whereas 44 patients in the placebo group and 37 in the bupropion group
completed the study per protocol. Results for the per-protocol population are reported in eTable 1,
eTable 2, eTable 3, and the eFigure in Supplement 2.
Demographic and screening characteristics and baseline outcome measures are listed in Table 1.
There were no substantial differences between the groups concerning demographic and screening
data (for the bupropion group vs the placebo group, mean [SD] age, 75.3 [5.5] years vs 74.4 [6.3]
years; mean [SD] education, 9.7 [3.1] years vs 9.9 [2.6] years; mean [SD] NPI apathy score, 7.2 [2.7] vs
7.4 [2.4]; mean [SD] NPI depression score, 0.6 [1.1] vs 0.4 [0.9]; median [interquartile range], NPI
depression score, 0.0 [0.0-1.0] vs 0.0 [0.0-0.0]; MMSE score >18, 34 patients [63%] in each group).
Outcome measures at baseline were comparable between the 2 groups (mean [SD] AES-C score,
52.2 [8.7] vs 50.4 [8.2]), except for the proxy rating of the QoL-AD, which was higher (equals better
quality of life) in the placebo group than in the bupropion group (mean [SD] score, 32.9 [4.5] vs
30.9 [5.2]).
Table 1. Demographic and Screening Characteristics and Outcome Parameters of Patients in Both Treatment
Groups (Intention to Treat Population) at Baseline
Characteristic
Mean (SD)
P valuea
All patients
(N = 108)
Bupropion group
(n = 54)
Placebo group
(n = 54)
Continuous variables
Age, y 74.8 (5.9) 75.3 (5.5) 74.4 (6.3) .39
Education, y 9.8 (2.9) 9.7 (3.1) 9.9 (2.6) .66
NPI item apathy score 7.3 (2.6) 7.2 (2.7) 7.4 (2.4) .68
NPI item depression score
Mean (SD) 0.5 (1.0) 0.6 (1.1) 0.4 (0.9)
.25
Median (interquartile range) 0.0 (0.0-0.0) 0.0 (0.0-1.0) 0.0 (0.0-0.0)
Categorical variables, patients, No. (%)
Male 67 (62.0) 31 (57.4) 36 (66.7) .32
Mini-Mental State Examination score >18 68 (63.0) 34 (63.0) 34 (63.0) >.99
Consent form signed by legal representative 28 (25.9) 14 (25.9) 14 (25.9) >.99
Comedication with donepezil
or galantamine
72 (66.7) 34 (63.0) 38 (70.4) .41
Primary outcome parameter, Apathy
Evaluation Scale-Clinician version total score
51.3 (8.5) 52.2 (8.7) 50.4 (8.2) .25
Secondary outcome parameters, score
Apathy Evaluation Scale-Clinician version
Cognition 24.0 (4.1) 24.5 (4.0) 23.5 (4.2) .22
Behavior 13.2 (2.5) 13.4 (2.7) 12.9 (2.3) .35
Emotion 4.9 (1.5) 5.1 (1.5) 4.8 (1.4) .26
Other 9.2 (1.9) 9.3 (1.8) 9.2 (2.0) .68
NPI total 16.2 (9.3) 16.4 (8.5) 16 (10.1) .83
NPI distress total 8.0 (5.8) 8.0 (6.1) 7.9 (5.5) .91
Alzheimer Disease Cooperative
Study–Activities of Daily Living
52.0 (16.8) 50.1 (17.4) 54 (16.1) .23
Alzheimer Disease Assessment
Scale–Cognitive Subscale
35.3 (12.1) 35.2 (12.6) 35.4 (1.6) .93
Mini-Mental State Examination 19.3 (4.1) 19.4 (4.1) 19.3 (4.3) .85
Montgomery-Asberg Depression Rating
Scale
9.2 (5.8) 9.9 (5.7) 8.4 (5.7) .12
Quality of Life in Alzheimer Disease Scale 37.6 (4.3) 37 (4.9) 38.1 (3.5) .21
Quality of Life in Alzheimer Disease Scale
proxy
31.9 (4.9) 30.9 (5.2) 32.9 (4.5) .03
Abbreviation: NPI, Neuropsychiatric Inventory.
a P values for continuous data were calculated with the
t test for independent groups. P values for
categorical data were calculated with the χ2 test.
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Results for the primary outcome measure are shown in Figure 2 and Table 2. There was no
statistically significant effect of bupropion compared with placebo on the mean change of the AES-C
total score between baseline and 12 weeks (mean change between groups, 2.22; 95% CI, –0.47 to
4.91; P = .11). There was numerically greater improvement of the AES-C total score in the placebo
group (mean change within group, 2.07; 95% CI, –0.06 to 4.21) than in the bupropion group (mean
change within group, –0.14, 95% CI, –2.34 to 2.05).
Results for the secondary outcome parameters are listed in Table 2. The difference in the mean
change in the emotional subfactor of the AES-C was statistically significant (mean change between
groups, 0.54; 95% CI, 0.04 to 1.03; P = .03) with a worsening in the bupropion group. There were
statistically significant differences for the mean change between baseline and 12 weeks for the NPI
total score (mean change between groups, 5.52; 95% CI, 2.00 to 9.04; P = .003) and the NPI
Caregiver Distress scale (mean change between groups, 3.03; 95% CI, 1.18 to 4.87; P = .002), with a
greater reduction in neuropsychiatric symptoms in the placebo group than in the bupropion group
(mean change within groups, 5.75 [95% CI, 3.02 to 8.49] vs 0.24 [95% CI, –2.56 to 3.04]) and a
higher reduction of caregiver’s distress in the placebo group than in the bupropion group (mean
change within groups, 2.36 [95% CI, 0.91 to 3.82] vs –0.66 [95% CI, –2.14 to 0.82]). There was a
statistically significant difference in the change on the MADRS between groups (mean change
between groups, 2.10; 95% CI, 0.53 to 3.67; P = .009) reflecting a mild improvement of subthreshold
depressive symptoms in the placebo group (mean change within group, 1.31; 95% CI, 0.10 to 2.51)
and a slight worsening the bupropion group (mean change within group, –0.79; 95% CI, –2.04 to
0.45). Finally, the QoL-AD self and proxy rating scales showed an improvement in quality of life in the
placebo group (mean changes within group, self rating, –0.43 [95% CI, –1.52 to 0.66]; proxy rating,
–1.95 [95% CI, –3.13 to –0.76]) and a worsening in the bupropion group (mean changes within group,
self rating, 1.23 [95% CI, 0.10 to 2.36]; proxy rating, 0.08 [95% CI, –1.17 to 1.32]). The mean change
between groups was statistically significant for the QoL-AD self rating (mean change between
groups, –1.66; 95% CI, –3.01 to –0.31; P = .02) and proxy rating (mean change between groups, –2.03;
95% CI, –3.58 to –0.47; P = .01). No statistically significant mean changes were found for the AES-C
subfactors cognition (mean change between groups, 1.03; 95% CI, –0.33 to 2.39; P = .14), behavior
(mean change between groups, 0.60; 95% CI, –0.34 to 1.55; P = .21), and other (mean change
between groups, 0.28; 95% CI, –0.37 to 0.93; P = .39), for the Alzheimer Disease Cooperative Study–
Activities of Daily Living Scale (mean change between groups, –2.92; 95% CI, –5.89 to 0.06; P = .05),
the cognitive subscale of the Alzheimer Disease Assessment Scale (mean change between groups,
–0.27; 95% CI, –3.26 to 2.73; P = .86), and the MMSE (mean change between groups, –0.45; 95% CI,
–1.84 to 0.94; P = .53).
Figure 2. Apathy Evaluation Scale-Clinician (AES-C) Total Score Over Time in Patients With Alzheimer Dementia
Receiving Bupropion or Placebo (Intention to Treat Population)
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The AEs and serious AEs are listed in Table 3; 39 bupropion-treated patients (72.2%) and 33
placebo-treated patients (61.1%) experienced at least 1 AE. Seven patients experienced a serious AE
leading to hospitalization (5 in the bupropion group [9.3%] and 2 in the placebo group [3.7%]). All
serious AEs were most likely unrelated to the study medication. No deaths occurred. Altogether, 157
AEs occurred in 108 patients. The bupropion group had more AEs per patient than the placebo group
(mean [SD], 1.8 [1.8] vs 1.1 [1.2] AEs; median [interquartile range], 1 [0-3] vs 1 [0-2] AEs). Of the 150
nonserious AEs, 94 (62.67%) occurred in bupropion-treated patients and 56 (37.33%) in placebo-
treated patients. The most frequent AEs were gastrointestinal symptoms, which occurred more
Table 2. Results of the Mixed-Effect Model Repeated Measure (Intention-to-Treat Population)a
Parameter and group
Score, mean change (95% CI)
P valueWithin groups Between groups
Primary outcome parameter, AES-C total
Bupropion –0.14 (–2.34 to 2.05)
2.22 (–0.47 to 4.91) .11
Placebo 2.07 (–0.06 to 4.21)
Secondary outcome parameter
AES-C cognition
Bupropion 0.21 (–0.89 to 1.31)
1.03 (–0.33 to 2.39) .14
Placebo 1.24 (0.18 to 2.30)
AES-C behavior
Bupropion –0.12 (–0.89 to 0.64)
0.60 (–0.34 to 1.55) .21
Placebo 0.48 (–0.27 to 1.23)
AES-C emotional
Bupropion –0.54 (–0.94 to –0.14)
0.54 (0.04 to 1.03) .03
Placebo 0.00 (–0.39 to 0.38)
AES-C other
Bupropion 0.03 (–0.49 to 0.55)
0.28 (–0.37 to 0.93) .39
Placebo 0.31 (–0.19 to 0.82)
Neuropsychiatric Inventory total
Bupropion 0.24 (–2.56 to 3.04)
5.52 (2.00 to 9.04) .003
Placebo 5.75 (3.02 to 8.49)
Neuropsychiatric Inventory Caregiver Distress
Scale total
Bupropion –0.66 (–2.14 to 0.82)
3.03 (1.18 to 4.87) .002
Placebo 2.36 (0.91 to 3.82)
Alzheimer Disease Cooperative Study–Activities
of Daily Living
Bupropion 2.81 (0.47 to 5.15)
–2.92 (–5.89 to 0.06) .05
Placebo –0.11 (–2.37 to 2.16)
Alzheimer Disease Assessment Scale–Cognitive
Subscale
Bupropion –1.53 (–3.93 to 0.87)
–0.27 (–3.26 to 2.73) .86
Placebo –1.80 (–4.15 to 0.55)
Mini-Mental State Examination
Bupropion 0.05 (–1.08 to 1.17)
–0.45 (–1.84 to 0.94) .53
Placebo –0.40 (–1.51 to 0.71)
Montgomery-Asberg Depression Rating Scale
Bupropion –0.79 (–2.04 to 0.45)
2.10 (0.53 to 3.67) .009
Placebo 1.31 (0.10 to 2.51)
Quality of Life in Alzheimer Disease Scale
Bupropion 1.23 (0.10 to 2.36)
–1.66 (–3.01 to –0.31) .02
Placebo –0.43 (–1.52 to 0.66)
Quality of Life in Alzheimer Disease Scale proxy
Bupropion 0.08 (–1.17 to 1.32)
–2.03 (–3.58 to –0.47) .01
Placebo –1.95 (–3.13 to –0.76)
Abbreviation: AES-C, Apathy Evaluation Scale–Clinician version.
a Table shows difference between baseline and 12
weeks between treatment groups corrected for the
baseline score, site, and comedication with
donepezil and galantamine.
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often in the placebo group than in the bupropion group (10 patients [17.2%] vs 6 patients [6.1%]).
Other frequent AEs were sleeping difficulties (14 patients [18.9%] total), falls (8 patients [5.1%] total),
and unrest or confusion (7 patients [4.5%] each). None of the AEs occurred significantly more often
in the bupropion group than in the placebo group.
Discussion
In this study, which, to our knowledge, is the largest randomized clinical trial on apathy in DAT so far,
treatment with bupropion failed to improve apathy as measured with the AES-C in nondepressed
patients with DAT over a period of 12 weeks compared with placebo. Moreover, statistically
significant uncorrected differences in mean change between the treatment groups were found for
the NPI total score, NPI distress score, MADRS, and the QoL-AD favoring the placebo group.
Our findings were comparable to those of a recent randomized clinical trial35 of 40
nondepressed patients with Huntington disease, where bupropion was not effective in the
treatment of apathy as rated by an informant compared with placebo. In that study,35 a general
positive effect on apathy was observed by trial participation.
Support for the dopaminergic hypothesis of apathy came from a recent randomized clinical
trial20 with methylphenidate that showed a significant improvement of apathy. However, that
study20 did not control for depression, and almost 60% of the participants had concomitant
depression. Therefore, the decrease in apathy might also be associated in part with effects of
methylphenidate on depression, which has been reported in geriatric depression.36 Another
difference was the inclusion of patients with moderate dementia in our study (MMSE score, 10-25)
compared with the methylphenidate trial (MMSE score, 18).20 In less affected patients with mild
dementia and mild cognitive impairment, response to treatment might be better.20
The use of the AES-C as the primary outcome measure of this trial has to be discussed. At the
time when the study was conceptualized (2008-2009), the AES-C was the most used and standard
Table 3. Comparison of Adverse and Serious Adverse Events in Patients With Alzheimer Dementia Receiving
Bupropion or Placebo (Intention-to-Treat Population)
Adverse event
Patients, No. (%)
P valuea
All patients
(N = 108)
Bupropion group
(n = 54)
Placebo group
(n = 54)
Patients with adverse event 72 (66.7) 39 (72.2) 33 (61.1) .22
Patients with serious adverse event 7 (6.5) 5 (9.3) 2 (3.7) .24
Hospitalization for suspected
lymphoma
1 (1.4) 1 (1.9) 0
Hospitalization for hypoglycemia 1 (1.4) 1 (1.9) 0
Hospitalization for syncope 1 (1.4) 1 (1.9) 0
Hospitalization for urinary tract
infection
1 (1.4) 1 (1.9) 0
Hospitalization for atrial fibrillation 1 (1.4) 1 (1.9) 0
Hospitalization for coprostasis 1 (1.4) 0 1 (1.9)
Hospitalization for hematuria 1 (1.4) 0 1 (1.9)
Adverse events per patient, No.
Mean (SD) 1.5 (1.6) 1.8 (1.8) 1.1 (1.2) .04
Median (interquartile range) 1 (0-2) 1 (0-3) 1 (0-2)
All nonserious adverse eventsb 150 (95.5) 94 (95.0) 56 (96.6) .11
Gastrointestinal symptoms 16 (10.2) 6 (6.1) 10 (17.2) .03
Sleeping difficulties 14 (8.9) 10 (10.1) 4 (6.9) .50
Falls 8 (5.1) 7 (7.1) 1 (1.7) .14
Unrest or anxiety 7 (4.5) 6 (6.1) 1 (1.7) .20
Confusion 7 (4.5) 6 (6.1) 1 (1.7) .20
Hallucinations 5 (3.2) 5 (5.1) 0 .08
a P values for categorical data were calculated with the
χ2 test. P values for nonparametric data were
calculated with the Mann-Whitney U test.
b There were 99 adverse events in the bupropion
group and 58 adverse events in the placebo group,
for a total of 157 adverse events. The percentages in
this section are based on these totals. Listed is the
number of nonserious adverse events that occurred
in 5% of patients receiving bupropion.
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measure for apathy in DAT. Recently, it has been shown that the scale is a 1-dimensional test, with a
substructure that does not include all dimensions of apathy.37,38 Therefore, future studies should use
more advanced measures, such as the Dimensional Apathy Scale, that better discriminate between
apathy and overlap symptoms of depression, as well as between different apathy subdimensions.39
Because of the lack of an established pharmacological treatment of apathy in DAT,
nonpharmacological therapies, such as the use of information and communication technologies or
occupational therapy, are still first-line recommendations.40
Strengths and Limitations
A strength of this double-blind, placebo-controlled, randomized clinical trial was the exclusion of
patients with clinically relevant depression. This allowed the assessment of bupropion on apathy
without contamination of the treatment effect by changes in depressed mood.
A limitation of this study was that we failed to reach the estimated required sample size of 216
patients and that we stopped the trial after an interim analysis that found no beneficial effect of
bupropion on apathy. This entailed a relevant loss of statistical power. However, because of the lack
of an effect in favor of bupropion on apathy, a full recruitment of 216 patients would not have
resulted in a positive finding. The identification of suitable patients was difficult throughout the
study. Although apathy occurs independently of depressed mood in patients with DAT, most
potentially eligible patients in the respective outpatient clinics showed dysphoric mood in addition
to apathy. Also, nondepressed patients with apathy often did not seem to be distressed in a way that
they wished to participate in a clinical study. As a result of their apathy, volunteerism for trial-related
activities was often low, which might have led to a selection bias. In addition, we cannot exclude that
lack of motivation was associated with dropout. In some cases, caregivers considered apathy helpful
to maintain their daily caregiving activities and thus did not feel the need for treatment of apathy.
Furthermore, the study physicians had to be extensively trained to actively seek for signs of apathy
during clinical evaluation, because apathy was usually not reported. According to the present
analysis, which is both interim and final, however, there was no evidence for any effect of bupropion
on apathy.
In the placebo group, we observed improvements in scores on the NPI, the NPI Caregiver
Distress Scale, the MADRS, and the Qol-AD that were not present in the bupropion group. One
reason for this difference might be the higher rate of AEs in patients receiving bupropion compared
with those receiving placebo in the ITT population. This might also explain the higher dropout rate in
the bupropion group compared with the placebo group (per-protocol population, 37 of 54 patients
in the bupropion group vs 44 of 54 patients in the placebo group). In the per-protocol population,
the mean number of AEs was not different between the 2 treatment groups, suggesting that patients
who experienced AEs dropped out of the study. We could not exclude the possibility that data were
missing not at random (ie, as a result of unknown circumstances related to the trial treatments).
However, according to Molenberghs et al,34 the mixed-effect model repeated measures analysis
performed is stable even if the assumption of missing not at random is violated.
Conclusions
In this study, bupropion was not superior to placebo for the treatment of apathy in patients with DAT
and apathy in the absence of clinically relevant depression. Because of the substantial impact of
apathy on patients’ quality of life,3 more randomized clinical trials are needed to find an efficient
treatment. Future studies are required to further analyze the pathophysiological mechanisms and
neurotransmitter alterations underlying apathy in DAT.
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